Denmark-based H. Lundbeck A/S on Monday agreed to acquire Longboard Pharmaceuticals, Inc (NASDAQ:LBPH) for $60.00 per share in cash. The transaction is valued at approximately $2.6 billion in equity value and $2.5 billion (approximately 17 billion Danish krone) net of cash on a fully diluted basis. The M&A transaction is expected to close in the fourth quarter of 2024. Also Read: Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage. Longboard is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The company’s…